Timothy P. Lynch’s Stonepine Capital Portfolio: Top 5 Healthcare Stocks

3. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)

Stonepine Capital’s Stake Value: $19,222,000

Percentage of Stonepine Capital’s 13F Portfolio: 8.74%

Number of Hedge Fund Holders: 14

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company specializing in neurological therapies, is one of the top stock picks of Timothy Lynch’s Stonepine Capital from September this year. The investment firm owns 3.91 million shares in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), worth $19.2 million, representing 8.74% of Stonepine Capital’s Q3 investments. 

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) was acquired on October 11 2021 by Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), and now operates as a subsidiary of the acquiring company. 

On November 17, Northland analyst Carl Byrnes downgraded Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) to Market Perform from Outperform, keeping an $8.50 price target on the shares to reflect the impending takeover by Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), which he expects to conclude by the end of 2021 or Q1 2022.

Steven Boyd’s Armistice Capital is the largest stakeholder of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), with 4 million shares valued at $19.64 million. Overall, 14 hedge funds tracked by Insider Monkey were bullish on Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) as of Q3 2021, down from 15 funds in the preceding quarter.